Search

Search Results

• CHARACTERISTICS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA IN MULTI-TRANSFUSED PATIENTS WITH THALASSEMIA MAJOR. EXPERIENCE OF A SINGLE TERTIARY CENTER.

  Nikolaos Papadopoulos, Dimitrios Kountouras, Katerina Malagari, Maria Tampaki, Maria Theochari, John Koskinas

  e2020013

  2020-02-26

  https://doi.org/10.4084/mjhid.2020.013

  1897

  PDF: 1003

  HTML: 232

• PREVALENCE OF ß-THALASSEMIA MUTATIONS AMONG NORTHEASTERN IRANIAN POPULATION AND THEIR IMPACTS ON HEMATOLOGICAL INDICES AND APPLICATION OF PRENATAL DIAGNOSIS, A SEVEN-YEARS STUDY

  Mohammad Ehsan Jaripour, Kourosh Hayatigolkhatmi, Vahid Iranmanesh, Farhad Khadivi Zand, Zahra Badiei, Hamid Farhangi, Ali Ghasemi, Abdollah Banihashem, Reza Jafarzadeh Esfehani, Ariane Sadr-Nabavi

  e2018042

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.042

  2517

  PDF: 1031

  HTML: 428

  Supplementary table 1: 250

  Some of the mutation detection samples: 256

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4415

  PDF: 1508

  HTML: 766

• IS HEMOGLOBIN E GENE WIDELY SPREAD IN THE STATE OF MADHYA PRADESH IN CENTRAL INDIA? EVIDENCE FROM FIVE TYPICAL FAMILIES

  R S Balgir

  e2014060

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.060

  2494

  PDF: 920

  HTML: 7997

  Untitled: 218

• DISTRIBUTION OF DNA DAMAGE REPAIR GENE POLYMORPHISM hOGG1, XRCC1 and p53 AMONG SICKLE CELL DISEASE PATIENTS IN INDIA

  Sudhansu Sekhar Nishank

  e2015046

  2015-07-02

  https://doi.org/10.4084/mjhid.2015.046

  1640

  PDF: 826

  HTML: 1535

  Table Genotype and allele frequencies of hOGG1 codon 326 Ser>Cys and p53 72Arg>Pro polymorphisms among SCD patients and control group: 209

• Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

  NICOLA SGHERZA, Stefania Zucano, Angelantonio Vitucci, Antonio Palma, Francesco Tarantini, Daniela Campanale, Luigi Vimercati, Angela Maria Vittoria Larocca, Domenico Visceglie, Amalia Acquafredda, Angelo Ostuni, Daniela Di Gennaro, Carmen Vitucci, Silvio Tafuri, Pellegrino Musto

  e2022056

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.056

  1252

  HTML: 315

  PDF: 544

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2226

  PDF: 1207

  HTML: 2020

• Should every patient with MDS get iron chelation – probably yes.

  Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh

  e2017055

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.055

  2397

  PDF: 992

  HTML: 398

• LIVER IRON CONTENT (LIC) IN ADULTS WITH NON-TRANSFUSION DEPENDENT SICKLE CELL DISEASE (NT-SCD). CORRELATION WITH SERUM FERRITIN AND LIVER ENZYMES CONCENTRATIONS

  Vincenzo De Sanctis

  e2017037

  2017-06-20

  https://doi.org/10.4084/mjhid.2017.037

  4087

  PDF: 1035

  HTML: 1216

• Liver iron concentration and liver impairment in relation to serum IGF-1 levels in thalassaemia major patients: A retrospective study

  Vincenzo De Sanctis, Ashraf T Soliman, Giancarlo Candini, Christos Kattamis, Giuseppe Raiola, Heba Elsedfy

  e2015016

  2015-02-13

  https://doi.org/10.4084/mjhid.2015.016

  1681

  PDF: 1093

  HTML: 883